Study of Anlotinib Combined With Gemcitabine/Cisplatin in Advanced Nasopharyngeal Carcinoma

NCT03639467 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Nasopharyngeal Carcinoma
Metastatic Nasopharyngeal Carcinoma

Interventions

DRUG: Anlotinib plus gemcitabine/cisplatin

Sponsor

Chinese Academy of Medical Sciences